Research programme: condensate modifying oncology drugs
Alternative Names: c-mods; condensate modifying drugsLatest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Dewpoint Therapeutics
- Developer Dewpoint Therapeutics; Evotec SE
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Ovarian cancer